Key Highlights
- Aro Biotherapeutics raised $41.5M in a Series B funding round led by Cowen Healthcare Investments.
- Funding participants include Johnson & Johnson Innovation – JJDC, Inc., Northpond Ventures, Healthcap, and BVF Partners, L.P.
- Focus on advancing ABX1100, a novel treatment for Pompe Disease, with anticipated initial study data in 2024.
Source: Business Wire
Notable Quote
- “We are appreciative of the support provided by this syndicate of leading life science industry investors. Aro is well positioned to advance our pipeline and progress the field by leveraging our Centyrin platform to enable efficient and tissue-targeted delivery of siRNA. This funding enables us to continue to pursue our mission and bring new medicines to patients who desperately need more effective treatments.,” – Susan Dillon, Ph.D., Chief Executive Officer at Aro
SoH's Take
The recent funding secured by Aro Biotherapeutics is a significant milestone in the biotechnology sector, especially in the development of tissue-targeted genetic medicines. This Series B round not only reflects the industry’s confidence in Aro’s innovative approach and potential in treating diseases like Pompe Disease but also underscores the growing interest in targeted genetic therapies. The involvement of renowned investors and leaders in the life sciences industry further validates the potential of Aro’s Centyrin platform and its upcoming projects. The progress of ABX1100, particularly, will be closely monitored as it holds promise for addressing unmet needs in the treatment of Pompe Disease. This funding round could mark a pivotal moment for Aro Biotherapeutics in establishing itself as a leader in the field of targeted genetic medicine.
